Micro-nanoemulsion and Nanoparticle-assisted Drug Delivery Against Drug-resistant Tuberculosis: Recent Developments

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2023 Nov 30

PMID 38032192

Authors

Simpal Kumar Suman

Natarajan Chandrasekaran

C George Priya Doss

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is a major global health problem and the second most prevalent infectious killer after COVID-19. It is caused by () and has become increasingly challenging to treat due to drug resistance. The World Health Organization declared TB a global health emergency in 1993. Drug resistance in TB is driven by mutations in the bacterial genome that can be influenced by prolonged drug exposure and poor patient adherence. The development of drug-resistant forms of TB, such as multidrug resistant, extensively drug resistant, and totally drug resistant, poses significant therapeutic challenges. Researchers are exploring new drugs and novel drug delivery systems, such as nanotechnology-based therapies, to combat drug resistance. Nanodrug delivery offers targeted and precise drug delivery, improves treatment efficacy, and reduces adverse effects. Along with nanoscale drug delivery, a new generation of antibiotics with potent therapeutic efficacy, drug repurposing, and new treatment regimens (combinations) that can tackle the problem of drug resistance in a shorter duration could be promising therapies in clinical settings. However, the clinical translation of nanomedicines faces challenges such as safety, large-scale production, regulatory frameworks, and intellectual property issues. In this review, we present the current status, most recent findings, challenges, and limiting barriers to the use of emulsions and nanoparticles against drug-resistant TB.

Citing Articles

Sulforaphane Inhibits Oxidative Stress and May Exert Anti-Pyroptotic Effects by Modulating NRF2/NLRP3 Signaling Pathway in -Infected Macrophages.

Chen G, Shen L, Hu H, Feng Y, Wen D, Liu Y Microorganisms. 2024; 12(6).

PMID: 38930573 PMC: 11205970. DOI: 10.3390/microorganisms12061191.

References

Pooja D, Tunki L, Kulhari H, Reddy B, Sistla R . Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin. Chem Phys Lipids. 2015; 193:11-7. DOI: 10.1016/j.chemphyslip.2015.09.008. View

Kanwar R, Gradzielski M, Prevost S, Appavou M, Mehta S . Experimental validation of biocompatible nanostructured lipid carriers of sophorolipid: Optimization, characterization and in-vitro evaluation. Colloids Surf B Biointerfaces. 2019; 181:845-855. DOI: 10.1016/j.colsurfb.2019.06.036. View

Cobelens F, Suri R, Helinski M, Makanga M, Weinberg A, Schaffmeister B . Accelerating research and development of new vaccines against tuberculosis: a global roadmap. Lancet Infect Dis. 2022; 22(4):e108-e120. PMC: 8884775. DOI: 10.1016/S1473-3099(21)00810-0. View

Jagielski T, Bakula Z, Roeske K, Kaminski M, Napiorkowska A, Augustynowicz-Kopec E . Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2014; 69(9):2369-75. DOI: 10.1093/jac/dku161. View

Maretti E, Costantino L, Rustichelli C, Leo E, Croce M, Buttini F . Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. Int J Pharm. 2017; 528(1-2):440-451. DOI: 10.1016/j.ijpharm.2017.06.045. View

Jahagirdar P, Gupta P, Kulkarni S, Devarajan P . Intramacrophage Delivery of Dual Drug Loaded Nanoparticles for Effective Clearance of Mycobacterium tuberculosis. J Pharm Sci. 2020; 109(7):2262-2270. DOI: 10.1016/j.xphs.2020.03.018. View

Wu S, Chan H, Hsiao H, Jou R . Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Front Microbiol. 2021; 12:754249. PMC: 8569445. DOI: 10.3389/fmicb.2021.754249. View

Lee M, Mok J, Kim D, Shim T, Koh W, Jeon D . Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase.... Trials. 2019; 20(1):57. PMC: 6335682. DOI: 10.1186/s13063-018-3053-1. View

Malone L, Schurr A, Lindh H, McKenzie D, KISER J, Williams J . The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice. Am Rev Tuberc. 1952; 65(5):511-8. View

10.

Pai M, Kasaeva T, Swaminathan S . Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022; 386(16):1490-1493. DOI: 10.1056/NEJMp2118145. View

11.

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

12.

Song X, Lin Q, Guo L, Fu Y, Han J, Ke H . Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery. Pharm Res. 2014; 32(5):1741-51. DOI: 10.1007/s11095-014-1572-3. View

13.

Tsai N, Lee B, Kim A, Yang R, Pan R, Lee D . Nanomedicine for global health. J Lab Autom. 2014; 19(6):511-6. DOI: 10.1177/2211068214538263. View

14.

Roberts L . How COVID is derailing the fight against HIV, TB and malaria. Nature. 2021; 597(7876):314. DOI: 10.1038/d41586-021-02469-8. View

15.

Costa M, Andrade C, Montenegro R, Melo F, Oliveira M . Self-assembled monolayers of mercaptobenzoic acid and magnetite nanoparticles as an efficient support for development of tuberculosis genosensor. J Colloid Interface Sci. 2014; 433:141-148. DOI: 10.1016/j.jcis.2014.07.014. View

16.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

17.

Nikonenko B, Reddy V, Bogatcheva E, Protopopova M, Einck L, Nacy C . Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013; 58(1):587-9. PMC: 3910727. DOI: 10.1128/AAC.01254-13. View

18.

Gajendiran M, Gopi V, Elangovan V, Murali R, Balasubramanian S . Isoniazid loaded core shell nanoparticles derived from PLGA-PEG-PLGA tri-block copolymers: in vitro and in vivo drug release. Colloids Surf B Biointerfaces. 2013; 104:107-15. DOI: 10.1016/j.colsurfb.2012.12.008. View

19.

Maretti E, Rossi T, Bondi M, Croce M, Hanuskova M, Leo E . Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. Int J Pharm. 2013; 462(1-2):74-82. DOI: 10.1016/j.ijpharm.2013.12.034. View

20.

Kaniga K, Hasan R, Jou R, Vasiliauskiene E, Chuchottaworn C, Ismail N . Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol. 2021; 60(1):e0291920. PMC: 8769720. DOI: 10.1128/JCM.02919-20. View